All In Biotech

NDA 017788 · Mylan Institutional

Rimso-50

Dimethyl Sulfoxide · Intravesical

Novel

Last checked: Nov 20, 2026Latest source record: Aug 27, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Apr 4, 1978

Approved uses

1

Original approval plus efficacy supplements

Registered trials

69

12 Phase 3, 7 recruiting

FAERS reports

243

198 serious, 31 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 17, 2021.

INDICATIONS AND USAGE RIMSO-50 ® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50 ® has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 4, 1978 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • RIMSO-50 · DIMETHYL SULFOXIDE 50% · SOLUTION, INTRAVESICAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Dimethyl Sulfoxide" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective49
  • headache48
  • nausea48
  • off label use42
  • abdominal pain41
  • pain39
  • pyrexia39
  • dyspepsia28
  • fatigue28
  • constipation27
  • infusion related reaction27
  • malaise27

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20056
20062
20072
20085
200912
20104
201110
20123
20131
20143
201515
20164
201719
201814
201921
202016
202118
202221
202328
202410
202515
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rimso-50 (Dimethyl Sulfoxide)

2024 spending

$568K

Beneficiaries

105

349 claims

Per beneficiary

$5,410

$13.75 per unit

View as table
YearSpending
2020$646,201
2021$712,159
2022$583,889
2023$590,539
2024$568,071

Part B: Rimso-50 (Dimethyl Sulfoxide) · HCPCS J1212

2024 spending

$3.7M

Beneficiaries

701

5,614 claims

Per beneficiary

$5,260

2024 ASP limit $695.76 per unit

View as table
YearSpending
2020$3,865,516
2021$3,916,042
2022$3,630,550
2023$3,361,204
2024$3,687,484

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 187 on PubMed

Sponsor: Mylan Institutional

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.